Literature DB >> 8094167

Alcohol consumption, Lewis phenotypes, and risk of ischaemic heart disease.

H O Hein1, H Sørensen, P Suadicani, F Gyntelberg.   

Abstract

We have previously found an increased risk of ischaemic heart disease (IHD) in men with the Lewis phenotype Le(a-b-) and suggested that the Lewis blood group has a close genetic relation with insulin resistance. We have investigated whether any conventional risk factors explain the increased risk in Le(a-b-) men. 3383 men aged 53-75 years were examined in 1985-86, and morbidity and mortality during the next 4 years were recorded. At baseline, we excluded 343 men with a history of myocardial infarction, angina pectoris, intermittent claudication, or stroke. The potential risk factors examined were alcohol consumption, physical activity, tobacco smoking, serum cotinine, serum lipids, body-mass index, blood pressure, prevalence of hypertension and non-insulin-dependent diabetes mellitus, and social class. In 280 (9.6%) men with Le(a-b-), alcohol was the only risk factor significantly associated with risk of IHD. There was a significantly inverse dose-effect relation between alcohol consumption and risk; trend tests, with adjustment for age, were significant for fatal IHD (p = 0.02), all IHD (p = 0.03), and all causes of death (p = 0.02). In 2649 (90.4%) men with other phenotypes, there was a limited negative association with alcohol consumption. In Le(a-b-) men, a group genetically at high risk of IHD, alcohol consumption seems to be especially protective. We suggest that alcohol consumption may modify insulin resistance in Le(a-b-) men.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8094167     DOI: 10.1016/0140-6736(93)92987-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  11 in total

1.  Lewis phenotypes, leisure time physical activity, and risk of ischaemic heart disease: an 11 year follow up in the Copenhagen male study.

Authors:  H O Hein; P Suadicani; F Gyntelberg
Journal:  Heart       Date:  2001-02       Impact factor: 5.994

2.  Lewis phenotypes, insulin resistance, and risk of ischaemic heart disease.

Authors:  K Meeran; S R Bloom
Journal:  Br Heart J       Date:  1994-04

3.  A New Year toast ... to the cardioprotective effects of alcohol.

Authors:  M J Griffith
Journal:  Br Heart J       Date:  1995-01

4.  Modulation of haemostatic function and prevention of experimental thrombosis by red wine in rats: a role for increased nitric oxide production.

Authors:  T Wollny; L Aiello; D Di Tommaso; V Bellavia; D Rotilio; M B Donati; G de Gaetano; L Iacoviello
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

5.  Fucosyltransferase 3 polymorphism and atherothrombotic disease in the Framingham Offspring Study.

Authors:  Luc Djoussé; Samer Karamohamed; Alan G Herbert; Ralph B D'Agostino; L Adrienne Cupples; R Curtis Ellison
Journal:  Am Heart J       Date:  2007-04       Impact factor: 4.749

Review 6.  Moderate drinking and health. Implications of recent evidence.

Authors:  M J Ashley; R Ferrence; R Room; S Bondy; J Rehm; E Single
Journal:  Can Fam Physician       Date:  1997-04       Impact factor: 3.275

7.  Relations between amount and type of alcohol and colon and rectal cancer in a Danish population based cohort study.

Authors:  A Pedersen; C Johansen; M Grønbaek
Journal:  Gut       Date:  2003-06       Impact factor: 23.059

8.  Population based cohort study of the association between alcohol intake and cancer of the upper digestive tract.

Authors:  M Grønbaek; U Becker; D Johansen; H Tønnesen; G Jensen; T I Sørensen
Journal:  BMJ       Date:  1998-09-26

9.  Alcohol consumption, serum low density lipoprotein cholesterol concentration, and risk of ischaemic heart disease: six year follow up in the Copenhagen male study.

Authors:  H O Hein; P Suadicani; F Gyntelberg
Journal:  BMJ       Date:  1996-03-23

Review 10.  Ought low alcohol intake to be promoted for health reasons?

Authors:  C D Holman; D R English
Journal:  J R Soc Med       Date:  1996-03       Impact factor: 18.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.